<DOC>
	<DOCNO>NCT01234857</DOCNO>
	<brief_summary>This two-part study determine , : 1 ) combination ridaforolimus dalotuzumab improve progression-free survival compare exemestane ; 2 ) combination ridaforolimus dalotuzumab improve progression-free survival compare ridaforolimus dalotuzumab single agent , participant breast cancer .</brief_summary>
	<brief_title>A Study Ridaforolimus ( MK-8669 ) Combination With Dalotuzumab ( MK-0646 ) Compared Standard Care Treatment Estrogen Receptor Positive Breast Cancer Patients ( MK-8669-041 AM3 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Inclusion Criteria The prospective participant must meet , least , criterion eligible study participation . The participant : Has confirm diagnosis breast cancer metastatic locally advanced estrogen receptor positive human epidermal growth factor receptor 2 ( HER2 ) negative ; Is postmenopausal ; Is least 18 year age ; Has life expectancy least 3 month ; Has recurrence progression cancer prior treatment patient receive least one line endocrine therapy metastatic disease , OR patient 's cancer recur within 6 month last dose anastrozole letrozole ; Has available archival tumor specimen ; Has voluntarily agree participate signing informed consent . Exclusion Criteria If prospective participant meet criteria ( among others determine study staff ) NOT eligible study participation . The participant : Is receive systemic tumor therapy ; Has previously receive rapamycin rapamycin analog ; Has receive prior treatment insulinlike growth factor 1 receptor ( IGF1R ) inhibitor , phosphoinositide 3kinase ( PI3K ) inhibitor , experimental agent target PI3K , protein kinase B ( AKT ) , mammalian target rapamycin ( mTOR ) pathways ; Has know allergy macrolide antibiotic ; Has active infection require antibiotic ; Has significant uncontrolled cardiovascular disease ; Has poorly control Type 1 2 diabetes mellitus ; Is know human immunodeficiency virus ( HIV ) positive ; Has know history active Hepatitis B C .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>mTOR</keyword>
	<keyword>breast cancer</keyword>
	<keyword>estrogen receptor positive</keyword>
</DOC>